Journal article
High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study
Frontiers in pharmacology, Vol.12, pp.638556-638556
04/22/2021
DOI: 10.3389/fphar.2021.638556
PMCID: PMC8100592
PMID: 33967773
Abstract
Background:
Coronavirus disease 2019 (COVID-19) pandemic is continuing to impact multiple countries worldwide and effective treatment options are still being developed. In this study, we investigate the potential of high-dose intravenous vitamin C (HDIVC) in the prevention of moderate COVID-19 disease aggravation.
Methods:
In this retrospective before-after case-matched clinical study, we compare the outcome and clinical courses of patients with moderate COVID-19 patients who were treated with an HDIVC protocol (intravenous injection of vitamin C, 100 mg/kg/day, 1 g/h, for 7 days from admission) during a one-month period (between March 18 and april 18, 2020, HDIVC group) with a control group treated without the HDIVC protocol during the preceding two months (January 18 to March 18, 2020). Patients in the two groups were matched in a 1:1 ratio according to age and gender.
Results:
The HDIVC and control groups each comprised 55 patients. For the primary outcomes, there was a significant difference in the number of patients that evolved from moderate to severe type between the two groups (HDIVC: 4/55 vs. control: 12/55, relative risk [RR] = 0.28 [0.08, 0.93],
P
= 0.03). Compared to the control group, there was a shorter duration of systemic inflammatory response syndrome (SIRS) (
P
= 0.0004) during the first week and lower SIRS occurrence (2/21 vs 10/22,
P
= 0.0086) on Day 7 (6–7 days after admission). In addition, HDIVC group had lower C-reactive protein levels (
P
= 0.005) and higher number of CD4
+
T cells from Day 0 (on admission) to Day 7 (
P
= 0.04).” The levels of coagulation indicators, including activated partial thromboplastin time and D-dimer were also improved in the HDIVC compared to the control group on Day 7.
Conclusion:
HDIVC may be beneficial in limiting disease aggravation in the early stage of COVID-19 pneumonia, which may be related to its improvements on the inflammatory response, immune function and coagulation function. Further randomized controlled trials are required to augment these findings.
Details
- Title: Subtitle
- High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study
- Creators
- Bing Zhao - Ruijin HospitalMin Liu - Shanghai Public Health Clinical CenterPing Liu - Shanghai Public Health Clinical CenterYibing Peng - Ruijin HospitalJun Huang - Shanghai Institute of HypertensionMengjiao Li - Ruijin HospitalYihui Wang - Ruijin HospitalLiLi Xu - Ruijin HospitalSilei Sun - Ruijin HospitalXing QiYun Ling - Shanghai Public Health Clinical CenterJian Li - Shanghai Jiao Tong UniversityWenhong Zhang - Huashan HospitalEnqiang Mao - Ruijin HospitalJieming Qu - Ruijin Hospital
- Resource Type
- Journal article
- Publication Details
- Frontiers in pharmacology, Vol.12, pp.638556-638556
- Publisher
- Frontiers Media S.A
- DOI
- 10.3389/fphar.2021.638556
- PMID
- 33967773
- PMCID
- PMC8100592
- ISSN
- 1663-9812
- eISSN
- 1663-9812
- Grant note
- Ruijin Hospital Science and Technology Commission of Shanghai Municipality
- Alternative title
- Zhao et al
- Language
- English
- Date published
- 04/22/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984696752902771
Metrics
3 Record Views